Key result
Orgaran exhibits a relatively long elimination half-life of anti-Xa activity (24.5 +/- 9.6 h) compared to other low molecular weight heparins, with near 100% subcutaneous bioavailability.
Population
Humans, including healthy male volunteers
Comparison
Orgaran administered intravenously or… vs Fragmin, Fraxiparine and Clexane in a…
Design
Review
Authors
Loading...
May inform twice-daily dosing and renal adjustment for Orgaran; leaves open comparative outcome trials.
Orgaran has a distinct pharmacokinetic profile with a long anti-Xa half-life and high subcutaneous bioavailability, requiring twice-daily dosing for optimal thrombosis prophylaxis and dose reduction in severe renal failure.
Danhof et al. (2009) reported a review. Orgaran (Org 10172) vs. Other low molecular weight heparins (Fragmin, Fraxiparine, Clexane) was evaluated on Pharmacokinetic profiles (elimination half-lives of anti-Xa, anti-IIa, and IIaGI activities). Orgaran exhibits a relatively long elimination half-life of anti-Xa activity (24.5 +/- 9.6 h) compared to other low molecular weight heparins, with near 100% subcutaneous bioavailability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: